Constitutively active internal tandem duplication (ITD) in the juxtamembrane domain of Fms-like tyrosine kinase 3 (FLT3), a type III receptor tyrosine kinase, is the most common molecular defect associated with acute myeloid leukemia. Its presence confers a poor outcome in patients with acute myeloid leukemia who receive conventional chemotherapy. FLT3-ITD has therefore been considered to be an attractive molecular target for a novel therapeutic modality. We describe here the identification and characterization of Ki23819 as a novel FLT3 inhibitor. Ki23819 suppressed proliferation and induced apoptosis of FLT3-ITD-expressing human leukemia cell lines. The growthinhibitory effect of Ki23819 on MV4-11 cells was superior to that of SU11248, another FLT3 inhibitor (IC 50 o1 vs 3-10 nM). Ki23819 inhibited the autophosphorylation of FLT3-ITD more efficiently than that of wild-type FLT3. FLT3-ITD-dependent activation of the downstream signaling proteins ERK and STAT5 was also inhibited within similar concentration ranges. Thus, Ki23819 is a potent in vitro inhibitor of FLT3. Leukemia (2005) 19, 930-935.
Introduction
Fms-like tyrosine kinase 3 (FLT3) is the receptor for FLT3 ligand (FL), a hematopoietic growth factor. FLT3 is primarily expressed in immature hematopoietic progenitors as well as in some mature myeloid and lymphoid cells. [1] [2] [3] It belongs to the type III receptor tyrosine kinase (RTK) family that includes KIT, FMS and platelet-derived growth factor receptor. 4 Each member of this RTK family is highly homologous with the others, and contains five extracellular immunoglobulin-like domains, a single transmembrane domain, a juxtamembrane domain and a cytoplasmic tyrosine kinase domain split into two subdomains by a kinase insert domain. Signaling by RTKs requires ligand-induced dimerization, which results in autophosphorylation of tyrosine residues.
The most common molecular defect identified in patients with acute myeloid leukemia (AML) is an activating mutation of FLT3. In approximately 20-30% of patients with AML and 3% of patients with myelodysplasia, FLT3 contains internal tandem duplication (ITD) of the juxtamembrane. [5] [6] [7] [8] [9] [10] [11] More recently, a point mutation in the activation loop of the FLT3 kinase domain was found in 7% of AML and 3% of myelodysplasia patients.
10,12, 13 Both types of mutations lead to the constitutive activation of FLT3 tyrosine kinase activity. Introduction of FLT3-ITD into interleukin-3 (IL-3)-dependent hematopoietic cell lines, such as Ba/F3 and 32D cells, induces IL-3-independent proliferation. [14] [15] [16] [17] Ba/F3 or 32D cells transfected with FLT3-ITD are leukemogenic when injected into mice. 15 Furthermore, primary murine bone marrow progenitor cells retrovirally transduced with FLT3-ITD cause lethal myeloproliferative disease. 18 A growing number of clinical studies have revealed that the presence of FLT3-ITD in AML confers a poorer prognosis. [8] [9] [10] [11] Thus, FLT3-ITD has become a promising candidate as a molecular target for a novel therapeutic modality. Although several kinds of FLT3 inhibitors have been established in vitro, [19] [20] [21] [22] [23] [24] their activities as single agents have not been satisfactory in clinical studies, [25] [26] [27] [28] which encouraged us to seek other classes of FLT3 inhibitors. In this study, we demonstrate that Ki23819 is a novel potent inhibitor of FLT3 kinase in vitro and is a potential antileukemic agent against AML with mutant FLT3 receptors.
Materials and methods

Cell culture
MOLM13, THP-1, HL60 and K562 cells were maintained in RPMI supplemented with 10% fetal calf serum (FCS). 293 T cells were maintained in DMEM with 10% FCS. 32D cells and their transfectants were maintained in RPMI with 10% FCS and 0.25 ng/ml recombinant murine IL-3. MV4-11 cells were cultured in IMDM with 10% FCS. Penicillin and streptomycin were added to all media. All of these cells were incubated at 371C with 5% CO 2 .
Construction of FLT3 expression vectors
Wild-type human FLT3 (FLT3-WT) cDNA was generously provided by Dr Olivier Rosnet. 29 The FLT3 gene was excised from pCDSRa and subcloned into pCXN2, a mammalian expression vector. 30 Total RNA of MOLM13 cells was prepared according to the acid guanidium thiocyanate-phenol-chloroform method. 31 Total RNA of MV4-11 cells was obtained using RNeasy Protect Mini Kit (QIAGEN). The first-strand cDNA was reverse-transcribed using Tth DNA polymerase (Perkin Elmer) and the primer: 5 0 -CATTGCCCCTGACAACATAG-3 0 . To obtain the MunI-EcoRV fragment that contains the tandemly duplicated region of FLT3-ITD, PCR was performed using the forward primer MunI-F: 5 0 -CAACAATTGGTGTTTGTCTCCTCTT-3 0 and the reverse primer EcoRV-R: 5 0 -CATGATATCTCGAGCCAATCC AAAG-3 0 . The amplified fragment was digested with MunI and EcoRV and substituted for the corresponding region of FLT3-WT in pCXN2. The nucleotide sequence was confirmed by bidirectional sequencing.
Reagents and antibodies
Ki23819 and SU11248 were dissolved in dimethyl sulfoxide (DMSO) to create 1 mg/ml stock solutions that were stored at 41C. In each experiment, DMSO concentration was adjusted to 0.4%. Human recombinant FL was purchased from R&D systems. The following antibodies were used: the anti-FLT3 antibody (Santa Cruz), the anti-STAT5 antibody (Santa Cruz), the anti-phospho-p44/p42 MAP kinase (Thr202/Tyr204) antibody (Cell Signaling), the antibody to total MAP kinase (Cell Signaling), the anti-phospho-Akt (Ser473) antibody (Cell Signaling), the antibody to total Akt (Cell Signaling), the anti-GST antibody (Pharmacia), the peroxidase-conjugated goat anti-mouse antibody and the peroxidase-conjugated goat antirabbit antibody (BioRad). The anti-phosphotyrosine antibody (4G10) was generated from culture supernatant of mouse hybridoma.
Establishment of 32D cells stably expressing FLT3-WT or FLT3-ITD 32D cells were transfected either with the pCXN2 vector alone or with that containing FLT3-WT or FLT3-ITD by electroporation (25 mF, 500 V). Cells were selected in 0.8 mg/ml G418 in IL-3-supplemented culture and subsequently subjected to limiting dilution to isolate clones.
Transient expression of FLT3-ITD in 293 T cells
293 T cells were transiently transfected with plasmids containing FLT3-ITD by standard calcium phosphate method as described elsewhere. 32 Immunoprecipitation and Western blotting 32D cells expressing FLT3-WT or FLT3-ITD were serum-starved in RPMI supplemented with 0.5% FCS (without murine IL-3) for 6 h after being washed twice with the same medium. Cells were incubated with 50 ng/ml FL for 15 min at 371C if required. Approximately 5 Â 10 7 cells were exposed to various concentrations of Ki23819 for 1 h. 293 T cells transiently expressing FLT3-ITD were exposed to the compound without starvation. Cells were lysed in TNE buffer 33 containing a phosphatase inhibitor (1 mM sodium orthovanadate), a cocktail of protease inhibitors (1.5 mg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 5 mg/ ml leupeptin, 2 mM benzamidine, and 50 mg/ml soybean trypsin inhibitor). The nuclei and cell debris were removed by centrifugation at 15 000 g for 10 min. For immunoprecipitation, precleared lysates were mixed with 5 ml of each antibody and rotated for 2-16 h at 41C, and the protein was then recovered on protein G-Sepharose beads (Amersham Biosciences). The beads were washed four times with the TNE buffer, and resuspended in 20 ml 2 Â sodium dodecyl sulfate (SDS) sample buffer. These samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting with each antibody. The blots were visualized with an enhanced chemiluminescence (ECL) system (Amersham Biosciences).
Proliferation assays
Cells were seeded into 96-well plates at a density of 2.7 Â 10 3 cells per well and cultured for 2 days. MV4-11 cells were washed once with RPMI supplemented with 10% FCS and plated in the same medium. Various concentrations of Ki23819 were added, and proliferation was measured in triplicate at 72 h by using a WST-1-based colorimetric assay (Cell Counting Kit-8, Dojindo), according to the manufacturer's instructions. Proliferation is expressed as a percentage of vehicle-treated controls. Results are expressed as mean value7s.d. A representative figure of three independent experiments is shown.
Apoptosis assays
MV4-11 or MOLM13 cells were incubated with various concentrations of Ki23819 for indicated periods. Apoptosis was assessed by a fluorescein isothiocyanate (FITC)-labeled annexin-V/propidium iodide (PI) assay (BD Biosciences Pharmigen) using flow cytometric analysis. Cleavage of poly (ADPribose) polymerase (PARP) and levels of caspase 3 were measured as described elsewhere. 23 
Preparation of recombinant protein and in vitro kinase assay
The cDNA encoding the kinase domain of human FLT3 (residues 563-993) was cloned into a pFastBac1 vector (Invitrogen) to generate an N-terminally glutathione S-transferase (GST)-fused protein. Baculovirus was isolated using the Bacto-Bac baculovirus expression system (Invitrogen) and amplified in Sf9 cells. Suspension cultures of Sf9 cells in SF900II media (Invitrogen) were infected with the baculovirus, then collected and suspended in phosphate-buffered saline containing Protease inhibitor cocktail tablets (Roche) at 72 h after infection and cell lysate was prepared by sonication. Fusion protein was purified by glutathione-Sepharose 4B beads (Amersham Biosciences).
Ki23819 was dissolved in DMSO at 200 Â the final concentration and diluted 1:20 in kinase buffer (50 mM HEPES pH 7.0, 25 mM NaCl, 0.01 mM sodium orthovanadate, 0.01% bovine serum albumin). In all, 1 mg of GST-fused FLT3 protein was added to 35 ml of kinase buffer, and 5 ml of diluted Ki23819 and 5 ml of ATP solution (300 mM ATP, 10 mM MnCl 2 ) were added, and the mixture was incubated for 10 min at room temperature. Reactions were stopped by adding 12.5 ml of 5 Â SDS-Sample buffer (Daiichi Pure Chemicals). Reaction mixtures were resolved by SDS-PAGE and was probed with PY-20 (BD Biosciences Pharmingen), followed by incubation with the peroxidase-conjugated anti-mouse IgG (Amersham Biosciences). The density of each band was quantified using the public-domain software package Scion Image Beta 4.02 for Windows (Scion Corporation). IC 50 values were calculated by nonlinear regression analysis using GraphPad Prism (GraphPad Software, Inc.).
Results and discussion
Ki23819 inhibits autophosphorylation of FLT3
The FLT3 inhibitor Ki23819 is a quinoline-urea derivative, which was initially identified through screening of a compound library (Figure 1 ). We first evaluated the autophosphorylation status of FLT3 in human leukemic cell lines in the presence of graded concentrations of Ki23819. MOLM13 cells possess FLT3-
WT in addition to FLT3-ITD, while MV4-11 cells exclusively possess FLT3-ITD. 22 As shown in Figure 2a 
Ki23819 inhibits the proliferation of FLT3-ITD-positive cells
The growth-inhibitory effects of Ki23819 were tested on several human leukemic cell lines. Treatment of FLT3-ITD-positive cells, MV4-11 and MOLM13 cells, with Ki23819 for 72 h suppressed the proliferation with an IC 50 of o1 nM (Figure 3a) . In contrast, much higher concentrations were required to inhibit the growth of THP-1 cells, which exclusively express FLT3-WT, and HL60 and K562 cells, both of which lack detectable FLT3 expression (Figure 3a) . Of note, THP-1 and HL60 cells possess N-RAS mutation, and MV4-11 cells possess K-RAS mutation, while K562 cells express BCR/ABL fusion protein, all of which activate the downstream ERK pathway. 34 These results suggest that Ki23819 specifically suppresses the growth of FLT3-ITD-positive cells among various types of cells with the activated ERK pathway. We next compared the growthinhibitory effect of Ki23819 to that of SU11248, another FLT3 inhibitor. 23, 35 Ki23819 inhibited the proliferation of MV4-11 and MOLM13 cells at a 10-fold lower concentration than SU11248 (Figure 3b) , indicating a robust growth-inhibitory potency of Ki23819.
Ki23819 induces apoptosis in FLT3-ITD-positive cells
To determine whether the cytotoxic effects of Ki23819 on these FLT3-ITD-positive cells are due to the induction of apoptosis, we conducted annexin V binding assays using flow cytometry on Representative structure of Ki23819. Ki23819 is a quinoline-urea derivative. R1, aminoalkyl; R2, halogen; R3, alkyl. These effects, however, were not efficiently blocked by the treatment with Z-VAD-fmk, a pan-caspase inhibitor, suggesting that Ki23819-induced apoptosis of these cells is not predominantly caspase-dependent (data not shown).
Ki23819 inhibits FLT3-ITD more efficiently than FLT3-WT in 32D cells
To preclude the possibility that the effects of Ki23819 depend not only on FLT3-ITD but also on other genetic abnormalities, we used 32D cells, an IL-3-dependent murine myeloid cell line, into which we introduced MOLM-FLT3-ITD (''32D FLT3-ITD''), wild-type FLT3 (''32D FLT3-WT'') or empty vector (''Mock'').
Although MOLM-FLT3-ITD possesses two point mutations in the first repeat that are accompanied by amino-acid replacement (Figure 5a ), ligand-independent phosphorylation was distinctly observed in 32D FLT3-ITD cells (Figure 5b , left panel), indicating that this form of FLT3-ITD recapitulates activating mutation of FLT3. FL-independent autophosphorylation of FLT3-ITD was inhibited by Ki23819 in a dose-dependent manner, with an IC 50 of 3 nM. In contrast, higher concentrations of Ki23819 were required for inhibition of ligand-dependent autophosphorylation of FLT3-WT (IC 50 30 nM). Ki23819 had no effect on the expression level of FLT3 protein per se. These results suggest that Ki23819 inhibits constitutively activated FLT3-ITD more efficiently than ligand-activated FLT3-WT, as was also reported for several of other inhibitors. 19, 23 Further studies on the manner of ligand-independent autophosphorylation of FLT3-ITD may elucidate the mechanism that underlies the enhanced sensitivity to Ki23819.
36,37
Figure 4
Proapoptotic effects of Ki23819 on MOLM13 and MV4-11 cells. (a) MOLM13 (top) and MV4-11 cells (bottom) were exposed to Ki23819 at the concentration indicated at the top for the period indicated on the left. Early apoptosis (lower right quadrant) and cell death (upper right quadrant) were evaluated by annexin V and PI using a flow cytometric analysis. (b) Ki23819 induced cleavage of PARP and activation of caspase 3. MOLM13 and MV4-11 cells were incubated with Ki23819 for 24 h. Total cell lysates were subjected to Western blotting.
Figure 5
Ki23819 inhibits FLT3 expressed in 32D transfectants. Lysates of 32D FLT3-WT cells were prepared and evaluated as described above. Similar results were obtained in repeated experiments using other independent 32D FLT3-WT clones. (c) Ki23819 inhibits the factor-independent growth of 32D FLT3-ITD clones. Two independent 32D FLT3-ITD clones were cultured without IL-3 and treated with the indicated concentrations of Ki23819 for 72 h. Proliferation was assessed with a WST-1-based assay and expressed as a percentage of that in vehicle-treated controls.
Ki23819 inhibits the proliferation of FLT3-ITD-expressing 32D cells
Introduction of FLT3-ITD conferred IL-3-independent growth on 32D cells (data not shown), as previously reported. [14] [15] [16] As shown in Figure 5c , the proliferation of these 32D FLT3-ITD cells in the absence of IL-3 was suppressed by Ki23819 at concentrations comparable to those required for FLT3-ITD inhibition. In contrast, in the presence of IL-3, the proliferation of 32D FLT3-ITD cells was unaffected even upon treatment with 300 nM Ki23819 (data not shown), suggesting that Ki23819 may suppress cellular proliferation specifically through the inhibition of FLT3-ITD.
Ki23819 inhibits the FLT3-ITD-dependent phosphorylation of ERK and STAT5
FLT3 signal transduction has been reported to occur via several intracellular pathways, resulting in the activation of ERK, STAT5 and Akt. [14] [15] [16] As shown in Figure 6a , ERK and STAT5 were constitutively activated in 32D FLT3-ITD cells, whereas their phosphorylation was barely detectable in Mock or FLT3-WT cells. 14, 15, 17, 38 In 32D FLT3-WT cells, neither ERK nor STAT5 was activated even upon FL stimulation (data not shown). A moderate activation of Akt was observed in all of the clones. Ki23819 effectively inhibited constitutive activation of ERK and STAT5 in 32D FLT3-ITD cells (Figure 6b, left panel) . The inhibitor had no effect on the overall expression of either ERK or STAT5 protein. In parental 32D cells cultured with IL-3, Ki23819 had no inhibitory effect on ERK or STAT5 phosphorylation (Figure 6b, right panel) . These results indicate that Ki23819 suppresses the activation of ERK and STAT5 by specifically inhibiting FLT3-ITD. 
Conclusion
Novel FLT3 tyrosine kinase inhibitor Ki23819
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